De BerardisD, FornaroM, SerroniN, MariniS, PiersantiM, CavutoM, ValcheraA, MazzaM, GirinelliG, IasevoliF, PernaG, MartinottiG, Di GiannantonioM: Treatment of antipsychotic-induced hyperprolactinemia: An update on the role of the dopaminergic receptors D2 partial agonist aripiprazole. Recent Pat Endocr Metab Immune Drug Discov, 8:30–37, 2014.
2.
LiX, TangY, WangC: Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: Meta-analysis of randomized controlled trials. PLoS One, 8:e70179, 2013.
3.
UrbanJD, VargasGA, von ZastrowM, MailmanRB: Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways. Neuropsychopharmacology, 32:67–77, 2007.
4.
WahlR, OstroffR: Reversal of symptomatic hyperprolactinemia by aripiprazole. Am J Psychiatry, 162:1542–1543, 2005.
